Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Treatment Extension Study of Niraparib in Subjects Previously Treated in a GSK/TESARO Niraparib Study
2020-002667-53Phase 2Active
- Sponsor
- GSK
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in ovarian cancer, breast cancer and prostate cancer (PCa), sponsored by GSK. Primary endpoint: Long-term safety and tolerability of niraparib. Started Apr 2021; status: active.
02
Drugs
niraparib
03
Conditions
ovarian cancerbreast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on 2020-002667-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002667-53.